There were 1,669 press releases posted in the last 24 hours and 393,015 in the last 365 days.

Cardiac Pacemaker Market is likely to reach a landmark of USD 6.78 Billion by 2030 with a stable CAGR of 3.68%. Let’s take a quick look at the pivotal statics provided below.

The team of healthcare experts at Strategic Market Research have deciphered that the Market for Cardiac Pacemaker was worth USD 4.73 billion in 2020 & is likely to reach a substantial landmark of nearly USD 6.78 billion in 2030 with a stable CAGR of around 3.68%.

New York, United States, May 23, 2022 (GLOBE NEWSWIRE) -- A cardiac pacemaker is regarded as a medical device that helps in the generation of electrical impulses that are delivered by the electrodes to cause the chambers of the heart to contract, resulting in an adequate pumping of blood. By doing so, this device accurately regulates the functions of electrical conduction system of the heart. The continuous rise in the CVDs (Cardiovascular diseases), increase in cardiac surgeries, and the rise in awareness to undergo various heart surgery treatments worldwide are propelling the growth of the Cardiac Pacemaker Market throughout the anticipated time frame of 2020 to 2030. In terms of Product Outlook, the Implantable Cardiac Pacemakers segment led the market in 2020 with a share of around 63.75% of the entire market & based on region, North America showed its sheer dominance with a share of around 43.78%. However, the Asia-Pacific region showed the fastest rate of growth in the market with a robust CAGR value.


To get a first-hand overview of the report, Request a Sample at 

https://www.strategicmarketresearch.com/request-sample/cardiac-pacemaker-market


The report published by Strategic Market Research on Cardiac Pacemaker Market is ramified based on:

Product Outlook

  • Implantable Cardiac Pacemakers

o Single Chamber

o Dual Chamber

o Biventricular Chamber

  • External pacemakers


Type

  • MRI Compatible Pacemakers
  • Conventional Pacemakers


Applications

  • Arrhythmias

o Heart Blockage

o Long QT Syndrome

o Atrial Fibrillation

  • Congestive Cardiac Failure
  • Others


End-User

  • ASCs (Ambulatory Surgical Centers)
  • Hospitals & Cardiac Centers
  • Others

Regions:

North America

· USA

· Mexico

· Canada

· Rest of North America


Europe

· Germany

· France

· Russia

· Switzerland

· U.K

· Finland

· Turkey

· Netherlands 

· Belgium

· Spain

· Italy

· Rest of Europe


Asia Pacific

· China

· India

· Indonesia

· Thailand

· Japan

· South Korea

· Singapore

· Malaysia

· Philippines

· Australia

· New Zealand

· Rest of APAC


LAMEA

· Brazil

· Saudi Arabia

· Uruguay

· Argentina

· Rest of LAMEA


Make a Direct Purchase of the latest Cardiac Pacemaker Market Report published in the month of January 2022. Click the below link to initiate the purchase: 

https://www.strategicmarketresearch.com/buy-now/cardiac-pacemaker-market


Key factors enhancing the Market Growth:

  • The continuous rising prevalence of CVDs (cardiovascular diseases) is one of the most prominent factors that is accelerating the overall growth rate of the market worldwide. The AHA (American Heart Association) have delineated that the CVDs have caused around 868,662 fatalities in 2017. In 2018, in the United States, CHD (coronary heart disease) was regarded as one of the primary causes of death (around 42.1%), followed by stroke (nearly 17.0%), high BP (around 11.0%), Cardiac failure (close to 9.6%), arterial diseases (nearly 2.9%), & other CVDs (around 17.4%). 

      Moreover, the American Heart Association have also reported that nearly 82.6 million people in the U.S are currently suffering from one or more forms of cardiovascular disease (CVD), thus making it one of the leading causes of death for both men and women across the globe.

  • Due to the continuous surge in the number of CVDs, the governments worldwide have raised their funding for Cardiac Disease Management (such as cardiac resynchronization therapy, cardiac surgeries, etc.) which is fuelling the overall market growth to a great extent. The Lifespan Health System have asserted that in the USA, approximately 500k open-heart surgeries are conducted per year, such as coronary artery bypass & several other critical aortic surgeries. Also, in accordance with a new study, in the United States, more than 900,000 total cardiac surgeries are performed each year.

  • Moreover, the introduction of different types of pacemakers such as iPhone 12 pacemaker, acid pacemaker, Micra leadless pacemaker, and single chamber pacemaker, etc., are augmenting the market growth significantly.


In terms of Product Outlook, the ‘Implantable Cardiac Pacemakers’ dominated the market comprehensively.

By Product Outlook, the market is fragmented into Implantable Cardiac Pacemakers (Single Chamber, Dual Chamber, and Biventricular Chamber) & External pacemakers. The ‘Implantable Cardiac Pacemakers’ segment led the market with an overall share of almost 63.75% in 2020. The increase in the adoption of these sorts of devices for the treatment of cardiac failure, arrhythmias, as well as the ongoing clinical trial processes, are the pivotal factors that are fostering the overall growth of this segment. The World Heart Federation has stated that because of the growth of the ageing population and rise in the cardiovascular risk factors, the prevalence of cardiac failure has increased globally to an approximate value of 26 million, along with the additional number of undiagnosed cases worldwide.


By Type, the Conventional Pacemakers segment dominated the Market Growth in 2020

By Type, the market has been bifurcated into Conventional Pacemakers and MRI Compatible Pacemakers. The ' Conventional Pacemakers ' held the largest market share of around 52.37%. The continuous technological upgrades and their cost-effectiveness are the major factors that are driving the segment growth.

On the other hand, the ‘MRI Compatible Pacemakers’ segment held the fastest rate of growth from 2020-to 2030. In 2018, Mayo Foundation for Medical Education and Research asserted that around 78.36% of the patients having an implantable pacemaker required an MRI in due course of time


By Applications, the ‘Arrhythmias’ segment held the highest market share.

On the basis of Applications, the market has been broadly divided into Arrhythmias (Heart Blockage, Long QT Syndrome, & Atrial Fibrillation), Congestive Cardiac Failure, and Others. The 'Arrhythmias' held the largest proportion of the market share at approximately 39.21 % in 2020. The notable factors that are propelling this segment’s growth are obesity, smoking, excessive alcohol consumption, & other lifestyle disorders. As per the NIH (National Institute on Alcohol Abuse and Alcoholism), around 95k people (approximately 68k men & 27k women) die due to alcohol-related causes annually, thus making alcohol consumption the third-leading cause of death in the USA.


By End-User, the ‘Hospitals & Cardiac Centres’ dominated the market significantly in 2020 with the highest revenue share.

In terms of End-User, the market has been segregated into ASCs (Ambulatory Surgical Centers), Hospitals & Cardiac Centers, & Others. The ' Hospitals & Cardiac Centres dominated the market with a share of around 62.37% during the estimated time frame. The increase in the number of cardiac patient admissions & excellent reimbursement facilities during the surgeries are some of the pivotal factors that are enhancing this segment’s growth. The AHA (American Heart Association) has declared that the total number of cardiac patients in the hospitals is likely to rise by 23.6 Million in 2030.


North America continued to dominate the Cardiac Pacemaker market:-

Based on Region, North America was regarded as the largest market in 2020, with nearly 43.78% throughout the estimated period. With a continuous rise of the geriatric population having coronary heart diseases, rapid technological advancements like the advent of MRI compatible pacemakers, Bluetooth enabled pacemakers, etc. & the improvised regulatory approvals are stimulating the market growth of this region. The CDC has elucidated that in the USA, Coronary heart disease is regarded as the one of the most common type of heart disease that killed around 360,900 people in 2019. On the other hand, about 2 out of 10 deaths due to CAD (Coronary artery disease) occur in adults who are less than 65 years old.

On the other hand, the Asia Pacific region comprehensively held the fastest rate of growth during the time frame of (2020-2030) with a robust CAGR. The rise of government funding in the healthcare sector, especially for the improvisation of cardiac diagnosis & treatment in countries like Japan, India, and China, is accelerating the growth of this segment widely.


Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report.

https://www.strategicmarketresearch.com/pre-order-enquiry/cardiac-pacemaker-market


Some of the most prominent players prevailing in the Cardiac Pacemaker Market worldwide are:

  • Medtronic
  • Zoll Medical Corporation
  • Boston Scientific Corporation
  • MicroPort Scientific Corporation
  • Cook Medical
  • Osypka Medical GmbH
  • MEDICO SpA
  • Pacetronix, Oscor Inc
  • Lepu Medical
  • LivaNova
  • Pacetronix
  • BIOTRONIK, etc.


Kindly go through and get access to our comprehensive coverage of myriad number of healthcare reports published in the last three months: 
https://www.strategicmarketresearch.com/reports/healthcare


Recent Developments:

  • On March 21st 2022, ZOLL Medical Corporation successfully launched their Next Generation MCT Solution for the improvisation of various Patient Management Decisions in the largest ever MCT Trial conducted across the globe. The ZOLL AMS MCT (Arrhythmia Management System mobile cardiac telemetry solution) added some of the most upgraded biometric data with that of the traditional ones that would help the physicians to make more informed treatment plans in cardiac surgeries.

  • On January 14th 2022, MicroPort CRM received an FDA Approval in Japan for the launching of its Alizea Bluetooth Pacemaker. The Alizea pacemakers allow the cardiologists to monitor the devices remotely. On the other hand, the SmartView Connect home monitor is placed beside the patient’s bed for the purpose of regular transmission of the detailed reports to the cardiologist regarding the functioning of the pacing system, thus reducing the need for the patients to visit the hospital for simple routine examinations. Alizea pacemakers & the SmartView Connect home monitor work collaboratively and provide the cardiologist with timely alerts & transmissions that are triggered by patients thus enabling faster & efficient patient care.

  • On January 10th 2022, Medtronic announced that it had received the FDA approval for launching its Micra AV Transcatheter Pacing System in Japan. Micra AV possesses a lot of additional algorithms which detect cardiac movements’ accurately. This allows the device to adjust the ventricle vibes for coordination with the atrium, thereby providing "AV synchronous" pacing therapy to the patients suffering from AV blockage.

Related Reports:

Global Cardiac Rhythm Management Devices Market Report

SMR’s ‘Cardiac Rhythm Management Devices Market Report with Insights & Forecast 2030’ delivers a thorough understanding of the detailed market insights like its drivers, restraints, opportunities, etc. With an overall market size of around USD 16.29 Billion in 2020, the Global Cardiac Rhythm Management Devices Market Size is expected to grow up to USD 31.9 Billion by 2030 with a CAGR of nearly 6.5%. Key factors that are augmenting the market growth are the rise of cardiovascular cases, the advent of photo-plethysmography technology, and an increase in investments and grants. The essential companies that are involved are Stryker, Schiller, Medtronic, Boston Scientific Corporation, Koninklijke Philips N.V., Zoll Medical Corporation, BIOTRONIK, Abbott, ProgettiSrl, and LivaNova Plc, etc.


Global Coronary Stents Market Report

SMR’s ‘Coronary Stents Market Report with Insights & Forecast 2030’ delivers an excellent concept of the crucial market insights like drivers, restraints, opportunities, etc. In 2020, the Coronary Stents Market summed up to USD 8.171 Billion, and it’s likely to reach USD 11.237 billion by 2028, with a stable CAGR of 4.78 %. The substantial increase in the rate of CVDs (cardiovascular diseases) like stroke & heart attacks & the continuous rise in the geriatric population worldwide are the key factors that are propelling the market’s growth. The pivotal organizations that are associated with it are Abbott, C. R. Bard Inc., Terumo Corporation, Medtronic, Boston Scientific, Cook Medical, and MicroPort Scientific Corporation.


Global Sacral Nerve Stimulation Market Report

SMR’s ‘Sacral Nerve Stimulation Market Report with Insights & Forecast 2030’ elucidates a crystal clear concept of the various market insights like drivers, restraints, opportunities, etc. In 2020, the value of the Sacral Nerve Stimulation Market was around USD 2.87 billion. However, as per the SMR analysts, it is anticipated to foster up to USD 3.2 billion by 2028, representing a burgeoning CAGR of 14.07 %. The key factors that are responsible for the expedition of the market growth are the growth of various diseases such as urge incontinence, overactive bladder disorders, etc. and the rise of investments in R&D activities of the highly advanced technological products. The essential companies that are associated with this market are Cyberonics, Codman & Shurtleff, Axonics Modulation Technologies, NeuroPace, Medtronic, Uroplasty, Laborie, St. Jude Medical, Synapse Biomedical, IntraPace, Boston Scientific Corporation, Nevro Corp., etc.


Global Transcatheter Aortic Valve Replacement Market Report

SMR’s ‘Transcatheter Aortic Valve Replacement Market Report Insights & Forecast 2030’ provides a complete picture of the pivotal market insights like drivers, restraints, opportunities, etc. The Global Transcatheter Aortic Valve Replacement Market accounted for USD 3.9 billion in 2020, and it is projected to reach a remarkable landmark of around USD 9.3 billion by 2028, with a robust CAGR value of 13 %. The important facts that are continuously fuelling the market growth are the rising prevalence of CVDs (cardiovascular diseases) worldwide, the increasing usage of less invasive medicines & a rapid surge in the old age population. Also, the key players that are associated with this market are Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, Abbott, St. Jude Medical, JenaValve Technology, Bracco SpA, Transcatheter Technologies GmbH, JC Medical, NVT AG, etc.


Global Ventricular Assist Devices Market Report

SMR’s ‘Ventricular Assist Devices Market Report Insights & Forecast 2030’ outlines a complete idea regarding the distinct market insights like drivers, restraints, opportunities, etc. In 2020, the Global Ventricular Assist Devices Market summed up to a value of USD 1.3 billion, & it's forecast suggests that it will reach around USD 2.59 billion by 2030 at a CAGR of 7.13%. The vital factors that are accelerating the market growth are the rapid advancements in technology, the rise of cardiovascular diseases, the rise in the geriatric populationetc. Apart from that, the key players that are operating in this market are Abbott Laboratories, Abiomed Medtronic, Teleflex Incorporated, SynCardia Systems, Fresenius Medical Care AG & Co. KGaA, Getinge (Sweden), CardiacAssist Inc., Berlin Heart, Jarvik Heart Inc., SENKO MEDICAL INSTRUMENT Mfg. CO., LTD., CardioDyme, World Heart Corporation, etc.


Global Congestive Heart Failure (CHF) Treatment Devices Market Report

SMR’s ‘Congestive Heart Failure (CHF) Treatment Devices Market Report Insights & Forecast 2030’ provides a pellucid idea about the prevailing market insights like drivers, opportunities, restraints, etc. With a market share of nearly USD 16.19 Billion in 2020, The Congestive Heart Failure (CHF) Treatment Devices Market is predicted to grow to a value of approximately USD 35.97 Billion along with a CAGR value of 8.31%. The notable factors that are driving the market growth forward are significant lifestyle changes of people, Higher-stress levels, irregular Dietary habits, etc. The key companies that are associated with the market are Berlin Heart GmbH, Abiomed, Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, HeartWare International, Inc., Jarvik Heart, Inc., LivaNova PLC, Medtronic plc, ReliantHeart Inc., & St. Jude Medical, Inc.


About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup which is in the Introduction stage of the Product Life cycle or an established one which is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis or new geographical penetration and expansion.

Contact Us:
Strategic Market Research LLP.
Sunil Kumar 
US: +1-8317045538
UK: +441256636046
India: +91-8260836500
Email: info@strategicmarketresearch.com
Web: https://www.strategicmarketresearch.com
Blog: https://www.strategicmarketresearch.com/blog
Press Release: https://www.strategicmarketresearch.com/press-releases

Connect Us:
LinkedIn: https://www.linkedin.com/company/strategic-market-research/
Twitter: https://twitter.com/smrstrategic
Facebook: https://www.facebook.com/StrategicMarketResearch
Instagram: https://www.instagram.com/strategicmarketresearchsmr/


Primary Logo